Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines

Key Points

• The reporting of clinical uncertainties for cancer drugs lacks consistency between publications and guidelines.
• Discrepancies were noted in how journal articles and NCCN guidelines addressed the FDA's Benefit-Risk Framework for new drugs.
• This assessment spans cancer drugs approved from 2019 to 2022, highlighting areas requiring improved clarity.
• The findings stress the need for better guidelines to ensure consistency in reporting clinical trial uncertainties.